Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Adam Shaywitz, MD PhD
BioMarin Pharmaceutical
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Calgary, Alberta, Canada
- Facility name not stated
Toronto, Ontario, Canada
- Facility name not stated
Montreal, Quebec, Canada
- Facility name not stated
Sherbrook, Quebec, Canada
- Facility name not stated
Hamburg, Germany
- Facility name not stated
Belfast, Northern Ireland, United Kingdom
- Facility name not stated
Manchester, United Kingdom
- Facility name not stated
Oakland, California, United States
- Facility name not stated
Chicago, Illinois, United States
- Facility name not stated
New York, New York, United States
- Facility name not stated
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2012
- Primary completion
- 30 Nov 2014
- Completion
- 30 Nov 2014
- Last update posted
- 1 Feb 2016
- Registered enrollment
- 25
- Registry id
- NCT01609062
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.